Novo Holdings

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Sparrow Quantum specializes in developing deterministic single-photon sources for advancing light-matter interfaces in quantum technologies. With a focus on high efficiency, purity, indistinguishability, and outcoupling, the company's technology is based on over two decades of research at the Niels Bohr Institute.

Sylvan Inc. is a biotechnology company specializing in the production and distribution of mushroom spawns, including agaricus, pleurotus, and shiitake strains, as well as casing inoculum. Founded in 1946 and based in Kittanning, Pennsylvania, Sylvan has expanded its operations internationally, with production and sales facilities in multiple countries, including the Netherlands, France, Hungary, and South Africa. The company also offers disease control products and nutritional supplements for the mushroom industry. Additionally, Sylvan engages in solid-state fermentation technology, providing sustainable solutions for various sectors, including food, health, agriculture, and materials. With research and development facilities in the United States and France, Sylvan positions itself as an innovative partner for businesses seeking to enhance their growth through fungal biotechnology.

Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing medicines to treat fibrotic diseases by targeting extracellular matrix–associated proteins central to scar formation, with the aim of halting progression across diverse tissues and conditions.

Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.

Hillstar Bio is a biopharmaceutical company focused on developing precision immunotherapies for treating autoimmune diseases. Its innovative approach selectively targets and depletes harmful immune cells, sparing healthy ones, to address specific disease mechanisms and reduce the risks associated with chronic broad immunosuppression. The company aims to provide durable relief and immune reset for patients with autoimmune conditions, addressing unmet medical needs.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Biocomposites is a medical device company based in Keele, United Kingdom, founded in 1996, that develops, manufactures and markets calcium-based bone repair products to regenerate and repair bone and soft tissue, offering calcium sulfate and calcium phosphate bone substitutes such as STIMULAN, geneX, and Allogran-R, along with synthetic calcium composite devices Bilok and Biosteon for interference screws and suture anchors used in musculoskeletal infection management, bone and joint trauma, spine procedures, and sports injuries; these products are designed to accelerate bone growth, improve implant integration, and support surgical outcomes in orthopedic and spinal procedures.

Callio Therapeutics specializes in the development of advanced antibody-drug conjugates (ADCs) for cancer treatment. Their focus is on creating multi-payload ADCs, which allow for the targeted delivery of drug combinations to tumor cells, potentially maximizing therapeutic benefits and improving patient outcomes.

Newleos Therapeutics is a stealth-mode biotechnology company focused on developing safer and more effective treatments for neuropsychiatric disorders, aiming to improve mental health outcomes.

Founded in 2021, Commit Biologics is a Danish biotechnology company dedicated to developing innovative immunotherapy platforms for cancer treatment. Its proprietary platform employs b-specific domain antibodies to engage the body's innate immune response, targeting and destroying cancer cells.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Its platform enables targeted delivery of therapeutic genes to the CNS, enhancing autophagy and lysosomal function, with a focus on improving patient outcomes for conditions like ALS.

Numab Therapeutics is an oncology-focused biopharmaceutical company that designs and develops antibody-based and multispecific therapeutics for cancer, inflammatory diseases, autoimmunity, and related severe conditions. It employs a plug-and-play platform that reduces the randomness of discovery and aims to predictably yield mono- or multispecific antibody fragments with tailored pharmacokinetic properties to engage multiple targets. Founded in 2011 and based in Wädenswil, Switzerland, Numab pursues immuno-oncology and inflammation programs through this multispecific approach, prioritizing therapies with improved selectivity and potential clinical efficacy.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Orbis Medicines is a company that develops a macrocyclic chemistry and computational platform for oral macrocycle drug discovery. The platform generates macrocycle candidates, nCycles, optimized for oral bioavailability to advance therapeutics that historically faced development hurdles. Its pipeline centers on nCycle candidates targeting validated biologic targets that are typically addressed by injectable drugs, with the goal of enabling oral delivery of such therapies. The platform combines chemistry and computational methods to accelerate drug discovery toward challenging targets in unmet-need indications, supporting therapeutics designed to improve patient outcomes.

SiteOne Therapeutics is a San Francisco-based company developing innovative therapeutics and diagnostics for acute and chronic pain. Their lead candidates are selective inhibitors of the Naᵥ1.7 ion channel, aiming to treat pain safely and effectively without relying on NSAIDs or opioids.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

Benchmark Genetics is a prominent company in aquaculture genetics, specializing in the development of genetic material for various species, particularly salmon, shrimp, and tilapia. With extensive experience from 30 applied breeding programs across 16 countries, the company is recognized as a leading provider of genetics services in the industry. Their approach is innovation-driven, utilizing advanced breeding technologies such as Quantitative Trait Loci (QTL) and Genomic Selection. Benchmark Genetics places significant emphasis on customer collaboration, fostering long-term partnerships with leading aquaculture businesses to enhance genetic improvements and develop new products. In addition to their genetic offerings, the company provides comprehensive technical support to ensure clients maximize the potential of their genetic resources. Their dedicated sales teams include technical specialists knowledgeable about their focus species and various production systems, including Recirculating Aquaculture Systems (RAS).

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Kivu Biosciences, based in San Francisco, is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company aims to deliver superior therapeutics and rapidly advance transformative assets, operating discreetly while focusing on its innovative pipeline.

Based on our deep science and focused on patients in need.

Booster Therapeutics is a biotechnology company focused on developing drug modalities to regulate cellular homeostasis and eliminate toxic accumulations. Its primary goal is to reinstate balance within cells, enabling the prevention and treatment of diseases associated with aging.

Stingray Marine Solutions AS is a Norwegian technology firm based in Oslo, specializing in innovative solutions for the aquaculture industry, specifically in the removal of sea lice from fish. Founded in 2010, the company has developed an advanced optical delousing system that employs camera vision and laser technology to detect and eliminate sea lice from salmon in net pens. This automated process enhances fish health management by minimizing the need for physical handling of the fish, thereby increasing productivity in salmon farming. Stingray Marine Solutions operates as a subsidiary of Beck Engineering AS and has its origins in the entrepreneurial vision of Esben Beck, who has been involved in technology development since 1999.

Convergent Therapeutics is a biotechnology company developing radiopharmaceutical therapies for prostate cancer. Its proprietary platform links monoclonal antibodies targeting prostate-specific membrane antigen (PSMA) with alpha-emitting radionuclides, enabling precise delivery of radiation to cancer cells while minimizing exposure to healthy tissue.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke care.

Founded in Boston in 2016, Elektrofi is a preclinical-stage company focused on revolutionizing drug delivery. Its proprietary formulation system can efficiently process a wide range of therapeutic molecules, including large and complex proteins like monoclonal antibodies.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Draupnir Bio is focused on developing innovative cholesterol-lowering medications that aim to prevent heart blood clots more effectively than existing treatments. The company leverages a platform technology that explores the glycome to create novel therapeutics through advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. Draupnir Bio specializes in synthesizing, screening, and selecting potent heparan sulfate glycomimetic drug candidates that address cardiovascular, inflammatory, and infectious diseases. Additionally, the company is working on protein degraders that target extracellular disease proteins, which could potentially address a wide range of unmet therapeutic needs across various medical conditions, providing more convenient treatment options compared to traditional injectable therapies.

Asceneuron is a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. It focuses on orphan tauopathies, Alzheimer's disease, and Parkinson's disease.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

MATR Foods is a food-tech startup focused on creating fungi-based food ingredients. The company specializes in transforming byproducts into healthy food options, utilizing mushrooms, vegetables, and fruits to develop nutritious dishes. MATR Foods emphasizes natural nutrition in its offerings, providing organic vegetables and stuffing for various food products, such as steaks and buns. The company's mission is to deliver healthy food alternatives that are free from additives and not over-processed, catering to consumers seeking wholesome and innovative culinary choices.

AgNext Technologies Private Limited is an AgTech company dedicated to enhancing food quality assessment through AI-based technologies. The company provides a comprehensive software-as-a-service (SaaS) platform tailored for agribusinesses, enabling instant and automated analysis of food quality. By integrating hardware and software solutions, AgNext facilitates on-the-spot evaluations, thereby improving transparency, safety, and trust in the agricultural value chain. Additionally, AgNext's agricultural sensing platform leverages precision and digital agriculture technologies, utilizing imagery and Internet of Things (IoT) devices. This allows farmers to receive timely updates via a mobile application for crop monitoring, analysis, and record-keeping.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

CARGO Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies to overcome cancer treatment resistance and access barriers. The company focuses on addressing limitations of approved autologous CAR T therapies, including manufacturing constraints, long turnaround times, and reimbursement challenges, to broaden patient access to potentially curative treatments. Its programs aim to deliver novel solutions that improve cancer treatment outcomes and patient experience. One of its product candidates, CRG-023, is a tri-specific CAR T designed to overcome relapse by targeting multiple B-cell antigens (CD19, CD20, CD22) and addressing mechanisms such as antigen loss, insufficient co-stimulation, and T cell exhaustion.

CIRCTEC is a company specializing in pyrolysis technology to convert waste into renewable fuels and circular chemicals. It focuses on producing sustainable drop-in fuels and circular chemicals derived from end-of-life tires, addressing the significant waste generated annually in this sector. By operating at the intersection of innovation and technology, CIRCTEC aims to enhance sustainability within the chemical, petrochemical, and oil industries, contributing to a cleaner environment and promoting circular economy practices.

Single Use Support GmbH, founded in 2015 and headquartered in Kufstein, Austria, specializes in the manufacturing of heavy-duty single-use plastic containers and packaging products designed for the transportation of liquids, particularly in the pharmaceuticals and biopharma sectors. The company develops innovative bulk filling systems, including BULK.STREAM and RoSS.FILL, to enhance fluid logistics processes and minimize the risk of leakage or bio-contamination. By providing tailored packaging solutions, Single Use Support aims to improve the efficiency and safety of liquid transport, addressing the specific needs of its clients in the pharmaceutical industry.

Bluejay Therapeutics is a private biopharmaceutical company focused on developing curative treatments for infectious and liver diseases. Its initial program targets chronic hepatitis B, a widespread infection with unmet medical need, using two approaches: fully human IgG1 monoclonal antibodies against hepatitis B surface antigen and oral small-molecule inhibitors of HBsAg. The aim is to reduce viral surface antigen and restore adaptive immunity, potentially achieving a functional cure for HBV and enabling patients to regain immune control of infection. The company’s work also contemplates extending its approach to other viral liver diseases, including chronic hepatitis D.

Founded in 2021, Commit Biologics is a Danish biotechnology company dedicated to developing innovative immunotherapy platforms for cancer treatment. Its proprietary platform employs b-specific domain antibodies to engage the body's innate immune response, targeting and destroying cancer cells.

Reunion Neuroscience is a clinical-stage pharmaceutical company focused on developing therapeutic solutions for underserved mental health conditions. Its lead asset, RE104, is a proprietary psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.

Reduced is a food production company focused on creating natural flavor enhancers from upcycled produce and organic surplus materials. By utilizing ingredients such as seaweed, shore crabs, and byproducts from egg-laying chickens and bull calf bones, Reduced aims to minimize food waste while providing consumers with sustainable, high-quality food products. The company’s approach not only promotes environmental responsibility but also enhances culinary experiences, making healthy and flavorful options more accessible in kitchens and homes.

Founded in 2015 and based in Cambridge, Massachusetts, Obsidian Therapeutics develops next-generation controllable cell and gene therapies designed to extend adoptive immunotherapy to every cancer patient. Its innovative approach uses pharmacologic operating systems to precisely control protein activity in cells, enabling physicians to improve upon current cell therapies using simple, safe, orally-active marketed drugs.

Clasp Therapeutics develops precision oncology platforms to identify neoantigens from driver mutations in hard-to-treat cancers. Its technology enables the creation of targeted therapies that selectively bind to HLA-presented peptides, allowing for precise destruction of cancer cells across various tumor types.

Asgard Therapeutics is a private biotechnology company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company employs its proprietary TrojanDC technology to initiate immune responses by leveraging the biological properties of professional antigen-presenting cells. With a commitment to creating personalized and efficient gene therapy products, Asgard Therapeutics aims to expand its pipeline of off-the-shelf cancer treatments, particularly for patients with cancers that are resistant to traditional therapies. By activating tailored anti-cancer immune defenses, the company seeks to offer new therapeutic options for individuals in need of effective cancer treatment alternatives.

Lexeo Therapeutics is a fully integrated biotechnology company focused on developing adeno-associated virus (AAV)-mediated gene therapies. Its lead programs target both rare and non-rare monogenic diseases, with a preclinical pipeline that spans monogenic, hereditary, and acquired conditions across populations with unmet medical need. The company aims to advance clinical programs toward commercialization while maintaining an ongoing research collaboration with Weill Cornell Medicine’s Department of Genetic Medicine to inform and accelerate its preclinical and clinical work. By leveraging AAV-based approaches and collaborations, Lexeo Therapeutics seeks to transform treatment options for patients with genetic and complex diseases.

Orbis Medicines is a company that develops a macrocyclic chemistry and computational platform for oral macrocycle drug discovery. The platform generates macrocycle candidates, nCycles, optimized for oral bioavailability to advance therapeutics that historically faced development hurdles. Its pipeline centers on nCycle candidates targeting validated biologic targets that are typically addressed by injectable drugs, with the goal of enabling oral delivery of such therapies. The platform combines chemistry and computational methods to accelerate drug discovery toward challenging targets in unmet-need indications, supporting therapeutics designed to improve patient outcomes.

Catalent Pharma Solutions provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industries worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. Development and Clinical Services offers manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials, along with analytical chemical and cell-based testing, respiratory product formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology and product development. The Oral Technologies segment focuses on formulation, development, and manufacturing for oral dose forms, including conventional tablets and capsules, controlled-release formulations, and proprietary oral delivery technologies. The Sterile Technologies segment provides formulation and development for injectable drugs and fills products into vials, pre-filled syringes, bags, and other sterile formats, with blow-fill-seal technology for integrated dose form creation. Packaging Services delivers packaging for pharmaceuticals, biologics, consumer health, and veterinary products, including blisters, bottles, pouches, unit doses, and printed components.

Founded in India over five decades ago, Manipal Hospitals is a prominent healthcare provider with a network of 15 hospitals and three primary clinics. It offers comprehensive curative and preventive care for both domestic and international patients.

Elo Life Systems is a biotechnology company dedicated to enhancing human health through innovative food solutions. It aims to bridge gaps between food, agriculture, and health by partnering with stakeholders across the food systems value chain. Elo employs precision breeding technologies, genomics, data analytics, machine learning, and gene editing capabilities to develop healthier, more sustainable food options.

Cleveland Diagnostics is a commercial-stage company based in Cleveland, Ohio, focused on developing and commercializing innovative cancer diagnostic tests. Founded in 2013, the company specializes in creating non-invasive screening tools for various cancers, including prostate, breast, ovarian, lung, and certain neurological diseases. Their portfolio includes blood-based tests designed to enhance early detection and improve patient outcomes. Cleveland Diagnostics employs a proprietary solvent interaction analysis technology that examines protein biomarkers at a structural level, offering more precise insights into disease processes and enhancing test specificity. The company has established strategic collaborations with industry partners, such as Genomic Health, to advance its diagnostic capabilities.

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Doctor Anywhere is a Singapore-based telehealth company that provides on-demand healthcare solutions. Its digital platform offers quick access to health and wellness services, optimized for convenient lifestyle management.

EnergyRe is focused on advancing the clean energy transition through the development of energy infrastructure designed to decarbonize urban environments. The company specializes in building utility-scale projects, including onshore and offshore wind farms, solar generation facilities, and energy storage solutions. By enhancing the accessibility of affordable clean power, EnergyRe contributes to the modernization of electric grids, facilitating a more sustainable energy landscape.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Terremoto Biosciences is a biotechnology company that develops innovative drug delivery systems. Its platform enables the creation of optimized small-molecule medicines, aiming to enhance therapeutic benefits and potentially cure diseases.

MapLight Therapeutics is focused on discovering and developing innovative therapies for brain disorders. The company utilizes a unique platform that integrates single-cell transcriptomics with optogenetics, enabling the identification of novel drug targets. By leveraging these advanced technologies, MapLight aims to create effective treatments tailored to address complex neurological conditions. Founded in 2018 and based in San Francisco, California, the company is committed to advancing the understanding and treatment of brain disorders through its cutting-edge research and development efforts.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.

Paratek Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel tetracycline-based therapies to treat infectious diseases and related public health threats. Its lead programs center on omadacycline, a broad-spectrum tetracycline available in oral and intravenous forms for community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, urinary tract infections, and other serious infections, and sarecycline for acne and rosacea. The company emphasizes expertise in advanced tetracycline chemistry to address antibiotic resistance. Paratek collaborates with industry and academic partners, including licenses with Zai Lab and Allergan, a license with Tufts University to develop products for bacterial diseases, and a cooperative R&D agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline. Founded in 1996 and headquartered in Boston, Paratek aims to bring therapies that improve patient outcomes and address public health challenges.

HPNow develops on-site, autonomous hydrogen peroxide generation technologies for water and air treatment. The company's HPGen systems produce hydrogen peroxide on demand from water, electricity and air, enabling local purification and disinfection without reliance on transported or stored chemical disinfectants. The technology is designed to displace conventional chlorine and other toxic disinfectants across multiple sectors, delivering cost savings, reduced logistics, and higher yields while improving water, air and food safety and reducing environmental impact. By providing an eco-friendly biocide and oxygenator, HPNow serves industries seeking safer, localized disinfection solutions.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

Octave Health Group Inc. is a behavioral health provider based in New York that focuses on addressing the mental health needs of young urban professionals. Established in 2017, Octave offers therapy and coaching for a wide range of clinical conditions, including anxiety, depression, trauma, and relationship issues, as well as general emotional well-being concerns such as stress management and self-esteem. The company aims to create a proactive approach to emotional health, akin to the emphasis placed on physical fitness. Its services are designed to be easily integrated into clients' lives and are delivered by a team of experienced psychologists, therapists, and coaches. Octave's innovative model emphasizes accessibility and sustainability, setting a new standard for mental health care through comprehensive and personalized support tailored to individual client needs.

Ray Therapeutics develops optogenetic gene therapies to restore vision in patients with blinding retinal diseases. The company designs therapies that use bioengineered light-sensitive proteins delivered to targeted retinal cells via intravitreal injections, with the goal of improving visual function across various forms of retinal blindness and inherited retinal diseases. By combining gene delivery with optogenetic control, Ray Therapeutics aims to provide durable, long-term benefits from a single treatment, addressing diseases that lead to severe retinal degeneration. The company focuses on advancing research and development in this niche field to enable patients with limited or no light perception to regain functional sight, supporting efforts to study rare retinal conditions and translate laboratory insights into potential clinical therapies.

Sangon Biotech Co. is a biotechnology company founded in 2003 as a Sino-foreign joint venture, specializing in the research and development of chemical synthesis of DNA. Over the years, Sangon has established itself as a key player in the global biotechnology market, known for its expertise in DNA synthesis, sequencing, and gene synthesis. The company has invested significantly in its infrastructure, including a manufacturing and industrial base in Songjiang Industrial Park. Sangon offers a wide range of products and services, including molecular biology kits, biochemicals, synthetic genes, oligos, peptide synthesis, enzymes, and laboratory consumables. By providing affordable life science research tools and services, Sangon supports researchers in advancing basic research and product development in the life sciences field.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Adcendo is a biotechnology company focused on developing novel antibody-drug conjugates (ADCs) for cancer treatment. These ADCs target specific receptors overexpressed in various cancer forms with significant unmet needs, such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

Founded in 2019, Clever Care Health Plan specializes in Medicare Advantage plans that integrate Eastern and Western medicine. It offers culturally sensitive healthcare solutions, including acupuncture, herbal remedies, tai chi, qi gong, cupping, and moxibustion treatments. The company connects members to diverse networks of hospitals, doctors, brokers, and member advocates.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

Chromologics is a Danish biotechnology company that originated as a spin-out from the Technical University of Denmark. It develops natural food colorants derived from a fungal biotechnology platform and fermentation processes. The company's pigments are designed as a new generation of bio-based colorants with stability across a range of pH levels and temperatures, enabling their use in various food products and allowing businesses to replace carmine in current applications.

Aquafortus specializes in non-thermal crystallization technology aimed at recovering clean water and crystallizing salts from high-salinity brines. The company addresses the treatment needs of various industries, including cooling towers, mining, oil and gas, inland desalination, and flue gas desulfurization from power generation. By significantly reducing energy consumption, Aquafortus enhances the economic viability of liquid transportation, wastewater management, and zero liquid discharge processes. This innovative approach enables clients to lower their operating expenses while effectively managing high-salinity waste.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Elo Life Systems is a biotechnology company dedicated to enhancing human health through innovative food solutions. It aims to bridge gaps between food, agriculture, and health by partnering with stakeholders across the food systems value chain. Elo employs precision breeding technologies, genomics, data analytics, machine learning, and gene editing capabilities to develop healthier, more sustainable food options.

Spruce Biosciences is a biopharmaceutical company focused on developing therapies for rare endocrine disorders. Its pipeline includes tildacerfont for classic congenital adrenal hyperplasia in adults and children, with ongoing clinical development, and Tralesinidase Alfa in its portfolio. The company collaborates with Eli Lilly to research, develop, and commercialize compounds. Founded in 2014, Spruce Biosciences is headquartered in Daly City, California, and aims to deliver meaningful therapies for patients with rare endocrine diseases.

LePure Biotech, established in 2011 and headquartered in Shanghai, China, operates within the biotechnology and pharmaceutical sectors. The company specializes in the development and manufacturing of disposable biopharmaceutical process equipment and consumables, primarily focusing on products that facilitate the storage, transportation, filling, and leak detection of samples related to biosimilars, vaccines, and other biopharmaceutical applications. Its core offering is a disposable storage bag designed to meet the specific needs of these processes. Recently, LePure Biotech completed a B+ round of financing, which aims to fund the development of innovative products, establish a research and development center in the United States, enhance supply chain integration, and expand its R&D operations both domestically and internationally.

Evosep is a developer of clinical proteomics solutions focused on making protein analysis faster and more robust for clinical and large-scale studies. Its products include EVOSEP ONE, a separation tool for clinical omics, and EVOTIP, disposable trap columns for sample loading. The company aims to enable reproducible plasma performance, protein identification with short gradients, rapid generation of data-independent acquisition libraries, and scalable screening for biomarkers in large cohorts. Built on extensive nano-UHPLC R&D experience, Evosep designs system architectures that improve throughput while maintaining reliability for clinical diagnostics. Founded in 2016 and based in Odense, Denmark, Evosep collaborates with leading scientists to advance proteomics-driven diagnostics.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Doctor Anywhere is a Singapore-based telehealth company that provides on-demand healthcare solutions. Its digital platform offers quick access to health and wellness services, optimized for convenient lifestyle management.

iECURE is a gene editing company developing mutation-agnostic in vivo gene insertion therapies to treat rare, life-threatening liver disorders in children. Its approach seeks long-term, potentially curative treatment for metabolic liver diseases caused by loss-of-function mutations, with initial programs targeting ornithine transcarbamylase deficiency, citrullinemia type 1, and phenylketonuria.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Roslin Technologies develops stem cell technology to advance cultivated meat, with a focus on animal pluripotent stem cells, including perpetually self-renewing induced pluripotent stem cells, to enable scalable production. Its licensable cell lines are designed for high performance and scalability to support the commercial viability of cultivated meat producers and food companies across North America, Europe, and Asia. By delivering advanced cellular platforms, the company aims to reduce production costs and accelerate market entry, with a mission to improve protein production through disruptive technologies.

Kate Farms, Inc. is a company that specializes in producing plant-based meal replacement shakes and tube feeding solutions for both adults and children. Founded in 2011 and headquartered in Santa Barbara, California, with an additional office in Waltham, Massachusetts, the company focuses on developing formulas that prioritize easy digestion and nutritional quality. Utilizing organic, plant-based ingredients, Kate Farms' products are free from synthetic additives and common allergens such as dairy, soy, gluten, corn, and nuts. The offerings are designed to cater to a wide range of dietary and medical needs, serving patients with severe chronic diseases as well as those with less serious medical issues. Products are available through a network of retail stores across the United States and online, with options for both prescription and over-the-counter purchase.

MedGenome develops sequencing-based diagnostics and a research platform that combines genomics technologies, bioinformatics, computing, and big data analytics to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases in diverse populations. The platform enables high-end genetic diagnostic tests across immuno-oncology, infectious diseases, reproductive health, and rare diseases, and serves patients, pharmaceutical companies, and research institutions worldwide by delivering deep insights into diseases at the genetic and molecular level to advance global health.

Vestaron develops and manufactures peptide-based biologic crop protection products. Its offerings include Spear-T for thrips control in greenhouses, Spear-Lep for fruits and vegetables, and Leprotec for field use. Headquartered in Durham, North Carolina with a research center in Kalamazoo, Michigan, Vestaron aims to provide growers with effective, safe, and sustainable biopesticides.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. Utilizing a discovery platform centered on RNA biology, Inspirna identifies novel cancer targets that contribute to tumor growth and disease progression. The company is advancing several first-in-class oral small molecules, including RGX-202, aimed at treating patients with RAS mutant colorectal cancer, and RGX-104, which is in development for small cell lung cancer and non-small cell lung cancer. Through its microRNA-based target discovery approach, Inspirna seeks to provide effective treatment options for cancer patients by employing targeted therapies that leverage small molecules and biologics.